A relatively unbridled market with few reimbursement restrictions and a plethora of proactive regulatory incentives appear to be driving the trend towards more cancer drug approvals in the U.S. versus Europe.
Edge In U.S. Cancer Drug Development Spurred By Regulatory And Reimbursement Policies
